Skip to main content

BIIB

Stock

BIIB

Stock
Health Care
Drug Manufacturers - General

Performance overview

BIIB Price
Price Chart

Forward-looking statistics

Beta
0.34
Risk
25.18%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Company info

SectorHealth Care
IndustryDrug Manufacturers - General
Employees10K
Market cap$32.8B

Fundamentals

Enterprise value$22.4B
Revenue$9.8B
Revenue per employee
Profit margin15.07%
Debt to equity39.00

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$10.12
Dividend per share
Revenue per share$67.32
Avg trading volume (30 day)$191M
Avg trading volume (10 day)$169M
Put-call ratio

Macro factor sensitivity

Growth-1.4
Credit+7.1
Liquidity+0.8
Inflation-6.9
Commodities-1.2
Interest Rates-0.9

Valuation

Dividend yield0.00%
PEG Ratio7.98
Price to sales1.98
P/E Ratio7.98
Enterprise Value to Revenue2.28
Price to book1.15

Upcoming events

Next earnings dayMay 1, 2025
Next dividend day
Ex. dividend day

News

Biogen Begins Phase III Felzartamab Study for Third Kidney Disease

BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies.

Zacks Investment Research (July 1, 2025)
Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see benefits from AI, and more.

CNBC Television (May 28, 2025)
Biogen Analysts Lower Their Forecasts After Q4 Results

Biogen Inc BIIB reported better-than-expected earnings for its fourth quarter on Wednesday.

Benzinga (February 13, 2025)
Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short

Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth.  The biotech company issued a full-year 2025 adjusted earnings outlook of $15.25 to $16.25 per share, which fell short of the $16.34 per share that Wall Street was expecting.

CNBC (February 12, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free